There is an elevated risk that people with type 2 diabetes have for cardiovascular disease (CVD) and chronic kidney disease (CKD). In this webinar, we'll review recent CVOT trials in type 2 diabetes and how learnings from these informed trials for heart failure (HF) and diabetic kidney disease (DKD). We'll also look at recent trials that looked at using SGLT2 inhibitors as treatments for patients with HF and CKD, both with and without type 2 diabetes. There will also be an overview of updated guidelines.
This webinar is part of a series of educational activities presented by ADCES in association with AstraZeneca-US Medical Affairs, CVMD Division. This webinar is educational in nature and contains no promotional or product information. CE credit is not available for this activity.
At the end of this presentation, participants will be able to:
- Describe the elevated risk that patients with Type 2 diabetes have for cardiovascular disease (CVD) and chronic kidney disease (CKD)
- Discuss the continuum of disease progression for CVD and CKD